Sameer Desai, MD, discusses the changing treatment landscape for lymphomas.
Sameer Desai, MD, medical oncologist/hematologist, Regional Cancer Care Associates, discusses the changing treatment landscape for lymphomas.
In the field, molecular testing has helped to identify which lymphomas are aggressive and which are not. This has led to a slight shift from the standard treatment, Rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP), to new therapies. Further research is underway to determine which therapies are appropriate for each type of lymphoma.
In the second- and third-line settings, CAR T cells are the most exciting addition to the treatment landscape. Currently, the main focus of CAR T cells is limiting severe toxicity. Many patients who received with CAR T-cell therapy experience neurotoxicity and other events. The CAR T-cell agents that are currently being developed will likely be less toxic.